Real world experience of Brolucizumab in recurrent macular oedema in Retinal Vein Occlusions : 12 months follow up

Abstract

Purpose : To evaluate real world outcome in recurrent macular oedema secondary to retinal vein occlusion in relation to anatomical success , visual outcomes and safety of intravitreal brolucizumab injection at 1 year. Methods : Prospective, randomized study between July 2022 to June 2023 on 17 eyes of 32 patients. Patients were divided into Group 1 : BRVO with ME , Group 2 : CRVO with ME. BCVA, CMT, and number of injections at 1 year were evaluated. From beginning patients were treated on PRN basis. Results: Study included 17 eyes with a mean age of 63.65 (SD: 10.68) years, and among these, 7 (41.2% ) were diagnosed with BRVO and 10 (58.8%) with CRVO. There was statistically significant improvement BCVA at 12 months in both the categories (P < 0.0001). Mean CMT also reduced significantly in both categories at 12 months (P < 0.0001). Median number of injections required was 2.0, while mean interval between two injections was 4.06 (SD: 1.91) months. Conclusion: In real-world scenario, with 1 year follow up , brolucizumab is found to be efficacious and safe with less need injections and more interval free period in management of recurrent ME due to RVO’s